Blindsided by Perimenopause at 43: The Symptoms, the Hormone Shifts, and the Labs a Provider Orders

You had a steady cycle and steady moods, and then—seemingly overnight—you didn't. If a clinician told you that you're "too young" and to come back in a few years, you deserved a better answer. This is that better answer: what's actually shifting, and how a provider makes sense of it.

First, you're not imagining it—and you're not "too young"

Perimenopause is the transition leading up to menopause, and it commonly begins in the 40s but can start earlier. Menopause itself—defined as 12 consecutive months without a period—occurs at an average age of about 51 in the United States, which means the years of hormonal turbulence before it routinely arrive in the early-to-mid 40s ^[1][2]. The transition can last several years, and symptoms often appear while periods are still happening. So a regular-cycle-turned-unpredictable at 43 is not early in any unusual sense—it's a textbook window ^[1].

For anyone who reached menopause abruptly—for example after surgical removal of the ovaries—the shift is not gradual at all. Surgical menopause removes the main source of ovarian estrogen at once, and symptoms can be more sudden and pronounced because the body doesn't get the slow taper that natural perimenopause provides ^[3]. "Early menopause" (before age 45) and "primary ovarian insufficiency" (before 40) are recognized clinical situations that warrant their own ongoing plan, not a one-and-done handoff ^[3].

What's actually changing under the hood

The headline isn't simply "estrogen drops." In perimenopause, estrogen levels become erratic—swinging high and low—before they eventually decline. The clearest early signal is in the brain–ovary feedback loop.

• FSH (follicle-stimulating hormone) rises as the ovaries become less responsive. The brain's pituitary releases more FSH to coax follicles into action; as the ovarian reserve diminishes, FSH trends upward ^[2][4].
• Estradiol (E2), the main premenopausal estrogen, doesn't fall in a tidy line. During the transition it can spike and crash, which helps explain why symptoms feel unpredictable ^[1][2].
• Progesterone tends to decline earlier and more consistently, because cycles without ovulation (anovulatory cycles) become more common—often a factor in disrupted sleep and shifting moods ^[1].

Mapping symptoms to these shifts:

• Hot flashes and night sweats (vasomotor symptoms) are linked to estrogen's effect on the brain's temperature-regulating center. They are the most characteristic symptoms of the transition and affect a large majority of women ^[1][5].
• Broken sleep can come from night sweats, from lower progesterone (which has calming, sleep-supportive effects), and from the general instability of the transition ^[1][5].
• Mood changes—irritability, anxiety, low mood—track with fluctuating estrogen and disrupted sleep; the transition is a window of increased vulnerability to depressive symptoms for some women ^[5].
• Brain fog and concentration changes are commonly reported and recognized in the menopause-medicine literature as part of the transition ^[5].
• Joint aches are frequently reported during the transition and after estrogen loss, including after surgical menopause ^[3][5].
• Irregular, unpredictable cycles are the defining hallmark—periods may come closer together, further apart, or vary in flow as ovulation becomes inconsistent ^[1][2].

The labs a provider reviews—and why no single number tells the story

Here's the part dismissive visits often skip: perimenopause is largely a clinical diagnosis, made from your pattern of symptoms and cycle changes—not from one blood draw ^[2]. Because hormones swing day to day in the transition, a single "normal" result doesn't rule anything out. That said, an independent provider may order labs to build context, rule out mimics, and tailor a plan.

Common labs a provider may review:

• FSH. An elevated FSH supports a picture of declining ovarian function, but because it fluctuates, one value can be misleading—especially while cycles continue ^[2][4]. It's more informative in specific situations (for example, evaluating possible early menopause or primary ovarian insufficiency, where guidelines may call for repeat testing) ^[3].
• Estradiol. Reviewed alongside FSH and symptoms; a single level captures only a moment in a moving system ^[2].
• Thyroid (TSH, sometimes free T4). This is essential because an underactive or overactive thyroid can mimic perimenopause almost perfectly—fatigue, mood changes, irregular cycles, sleep trouble, weight shifts. Checking thyroid function helps separate the two ^[6].
• Other context labs a provider might consider depending on your story can include markers related to ovarian reserve, iron status (heavy bleeding can cause anemia), or metabolic and bone-health context—chosen individually, not as a fixed panel.

For someone who had a hysterectomy, the lab picture differs. If the ovaries were removed, the estrogen drop is abrupt and the diagnosis is anatomical rather than mystery; if the uterus was removed but ovaries left in place, there's no period to track—so symptoms and labs carry more of the diagnostic weight ^[3]. Either way, this is a situation that benefits from an ongoing plan and follow-up, not a single appointment.

How providers think about support (educational, not a prescription)

For symptomatic women in the transition or after menopause, menopausal hormone therapy is one recognized option that clinicians discuss; for women with a uterus, estrogen is generally combined with a progestogen to protect the uterine lining, and for those after hysterectomy, estrogen-alone regimens are often considered ^[5]. Decisions are individualized around your age, time since menopause, symptoms, and personal and family health history—and the benefit-risk balance is part of every conversation ^[5]. None of this is a recommendation; whether any therapy is appropriate is a decision an independent licensed provider makes with you.

Some women encounter compounded hormone products in their research. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.

What to bring to a visit

You can make a single visit far more useful by arriving with data. Consider tracking, for a few weeks to a few months: cycle dates and flow, sleep quality, hot flashes/night sweats, and mood patterns. A clear symptom timeline often does more to drive a thoughtful plan than any one lab value—and it directly counters the "come back in a few years" brush-off.

This article is educational and is not medical advice, diagnosis, or treatment. Talk with a licensed provider about your individual situation.

Where Velri fits

Velri is a technology and coordination company—not a medical practice. We help organize the parts of the process so you don't have to chase them down: coordinating lab work where appropriate, connecting you with an independent, licensed provider group for an evaluation that takes your stage seriously, and—only if a provider determines it's appropriate—coordinating with an independent licensed pharmacy. A prescription is never guaranteed; any clinical decision rests entirely with the independent provider. The goal is continuity: a place where early or surgical perimenopause is heard, mapped to mechanism and labs, and followed over time rather than handed off.